UNIQUE PROBIOTIC STRAIN FOR THE MANAGEMENT OF INSULIN RESISTANCE & PRE-DIABETES
L. plantarum A7 (DSM 33132)
Recommended dosage: 3 billion cells per day (better combined with 100mg of mulberry leaves)
Scientific Data
Probiotics were investigated in an in vitro diabetic model, with regard to hyperglycemia, insulin resistance, hypercholesterolemia and dyslipidemias. In particular, the following were analyzed:
- analysis of cytotoxicity and production of reactive oxygen species
- the main markers involved in glucose metabolism (such as AKT, GLUT4 and PGC-1)
- cardiovascular risk analysis on endothelial and cardiac cell co-culture model
To better understand the effect, after the first screening the most effective combinations were studied in a complete cardio-metabolic model, including the intestinal passage up to the cardiovascular risk control:
- evaluation of liver damage
- analysis of free cholesterol levels
- lipids accumulation and circulating LDL
- inflammatory picture and pro-inflammatory cytokines analysis
Results
Contact us to receive more information
Key Points
- Exclusive Probiotic strain L. plantarum A7 (DSM 33132)
- Demonstrated effective and synergically combined with Reducose® (white-mulberry leaves extract patented ingredient, clinically studied for the support of healthy blood sugar response) [clinical effective dosage = 200mg per serving]
- Studied in a pre-clinical in vitro human model of gut-pancreas axis under diabetic condition
- Scientific communication under submission Patented probiotic strain
- Without food allergens Reg. 1169/2011
